Cost-effectiveness Analysis of Fluorouracil, Leucovorin, and Irinotecan versus Epirubicin, Cisplatin, and Capecitabine in Patients with Advanced Gastric Adenocarcinoma

No standard treatment has been accepted widely for the first-/second-line therapy for advanced gastric cancer (AGC). The current study aimed to determine a preferred strategy between FOLFIRI (fluorouracil, leucovorin, and irinotecan) and ECX (epirubicin, cisplatin,and capecitabine) for AGC from the...

Descripción completa

Detalles Bibliográficos
Autores principales: Wen, Feng, Zheng, Hanrui, Wu, Yifan, Wheeler, John, Zeng, Xiaoxi, Fu, Ping, Li, Qiu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5099909/
https://www.ncbi.nlm.nih.gov/pubmed/27824060
http://dx.doi.org/10.1038/srep36060

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5099909/
https://www.ncbi.nlm.nih.gov/pubmed/27824060
http://dx.doi.org/10.1038/srep36060

Ejemplares similares